Health Desk July 20, 2026 at 02:53 AM 2 min readhealth

CDSCO Approves Wegovy For MASH Treatment In Adults With Liver Fibrosis

CDSCO Approves Wegovy For MASH Treatment In Adults With Liver Fibrosis
The Bottom Line
  • •CDSCO has approved Wegovy for MASH treatment, offering new hope for patients with liver fibrosis.
  • •Increased accessibility through price reductions is expected to support the rollout of this therapy.
Advanced Analytics & Sharing
We are building interactive sentiment charts, trend forecasting, and social sharing tools. Stay tuned!

[The Event]:

The Central Drugs Standard Control Organization (CDSCO) has officially approved Novo Nordisk's Wegovy, a semaglutide injection, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) in adults. This approval specifically targets patients suffering from moderate to advanced liver fibrosis, marking a significant advancement in therapeutic options for this condition.

[The Why]:

MASH is a progressive liver disease that has historically lacked effective pharmacological interventions. The approval of Wegovy, which contains semaglutide at a 2.4 mg dosage, provides a new pathway for managing the condition. Emcure Pharmaceuticals, which acts as the exclusive domestic distribution partner for semaglutide under the brand name Poviztra, has already taken steps to improve accessibility by reducing the starting monthly price to approximately ₹3,999, down from the previous ₹8,790.

[What Next]:

With the regulatory hurdle cleared, the focus now shifts to the rollout and adoption of the treatment across Indian hospitals and clinics. Patients with moderate to advanced liver fibrosis may soon have broader access to this therapy, potentially improving long-term health outcomes for those struggling with metabolic liver dysfunction.
Pulse Intelligence
Context & Impact
Context & Background
  • CDSCO is the primary regulatory body overseeing drug approvals in India.
  • Emcure Pharmaceuticals is the exclusive domestic distribution partner for semaglutide under the brand name Poviztra.
  • The price of the semaglutide injection was reduced by the distributor earlier in April 2026.
Key Consequences
  • Patients with MASH and liver fibrosis will have access to a new, approved treatment option.
  • The reduced pricing strategy by Emcure Pharmaceuticals may facilitate wider adoption of the therapy.
  • Healthcare providers will need to update treatment protocols to incorporate the use of semaglutide for MASH.
Market & Economic Impact

Not applicable.